Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Alzheimer's Disease
NCT03801642Phase 2Completed
- Start
- Jan 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in Alzheimer's disease (AD). Started Jan 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03801642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03801642.